MedGenome vs Predible Health

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. MedGenome employs 200-500 people, while Predible Health has 10-50 employees.

MedGenome has raised more in total funding at $50M, compared to Predible Health's $5M — a gap of $45M.

MedGenome holds the higher Awaira Score at 63/100, compared to Predible Health's 50/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 13-point gap that reflects meaningful differences in scale or traction.

MedGenome was founded by Sam Santhosh in 2013. Predible Health was founded by Sanjoy Paul in 2017. Visit each company's profile on Awaira for a full founder biography.

MedGenome: MedGenome is a genomics and precision medicine company that combines next-generation sequencing with AI-powered data analysis to deliver clinical genomic testing for rare diseases, hereditary cancers, and pharmacogenomics. The company operates a NABL-accredited genomics laboratory and a bioinformatics platform that interprets variant data against proprietary South Asian population databases.\n\nThe company raised approximately $50M across Series B and C rounds from investors including Sequoia India and CDC Group, and serves hospitals, research institutions, and pharmaceutical companies across India and Southeast Asia. MedGenome has built one of the largest repositories of South Asian genomic data, which is clinically significant given that most reference genome databases are biased toward European populations.\n\nThe underrepresentation of South Asian genetic variation in global genomic databases creates both a clinical risk and a commercial opportunity. MedGenome's proprietary database of South Asian genomic variants and its AI-powered interpretation capabilities represent a durable competitive asset as personalized medicine adoption grows across the Indian healthcare system. Predible Health: Predible Health develops AI software for radiology and medical imaging analysis, with a focus on automated CT scan interpretation for lung nodule detection, COVID-19 assessment, and liver segmentation. The platform integrates with radiology information systems and PACS to provide AI-assisted second reads and quantitative measurements that reduce reporting time and flag critical findings for urgent review.\n\nThe company raised approximately $5M in Series A funding and has established clinical partnerships with hospital networks and diagnostic imaging centers across India. Predible Health received significant validation through its COVID-19 CT analysis tool, which was deployed during the pandemic to help overwhelmed radiology departments manage surge volumes.\n\nRadiology AI represents one of the most commercially mature segments of medical AI globally, with clear clinical workflows, measurable radiologist productivity benefits, and established reimbursement pathways emerging in developed markets. Predible Health's India-focused deployments position it as a domestic alternative to global radiology AI companies, with the advantage of deep integration knowledge in Indian hospital IT environments.

MedGenome was founded first in 2013, giving it 4 years of additional market experience. Predible Health was founded later in 2017. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

MedGenome has approximately 200-500 employees, while Predible Health has approximately 10-50. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, MedGenome and Predible Health are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.